Targeting the programmed cell death protein-1 pathway (PD-1/PD-L1) and cytotoxic T lymphocyte–associated antigen-4 (CTLA-4) has led to important clinical advances in cancer therapy [107,108,109]. The gene discussed is PDCD1; the disease is cancer.